Full text is available at the source.
Abstract
Patterns of discontinuation and reinitiation of subcutaneous semaglutide and tirzepatide were examined in adults with obesity but without diabetes.
- Discontinuation and reinitiation patterns of GLP-1 receptor agonists in non-diabetic adults with obesity are not well characterized.
- The study focuses on real-world usage of semaglutide and tirzepatide in an academic medical center.
- Transitions between semaglutide and tirzepatide, as well as switches to first-generation antiobesity medications, were also evaluated.
Simplified